Revised SPC: Gazyvaro (obinutuzumab) 1,000 mg concentrate for solution for infusion

Further information from the pivotal clinical study has been added to the SPC, including updated information on adverse effect frequency, and efficacy results at final analysis (median observation time of 45.9 months).

Source:

electronic Medicines compendium